Hemispherx BioPharma, Inc (NYSEAMEX:HEB) Investor Files Lawsuit in Connection New Drug Ampligen
A lawsuit was filed for certain investors in shares of Hemispherx BioPharma, Inc (NYSEAMEX:HEB) over alleged securities laws violations. Deadline: February 22, 2013. NYSEAMEX:HEB investors, who purchased a substantial amount of shares, should contact the Shareholders Foundation.
View full press release